It has been responsible for the UK distribution of these prescription-only medicines – which are used in the management of attention-deficit hyperactivity disorder (ADHD) – since their launch, on behalf of the marketing authorisation holder Medice GmbH, Germany.

However, from 1 January 2023, responsibility for distributing these products transferred to Medice UK, Flynn Pharma said.

Flynn Pharma has already endeavoured to inform its wholesalers, supply chain partners, and pharmacies of the changes so as to minimise, if not prevent, any disruption to patient care, which is and remains at the forefront of its consideration, it said.

Its 15-year involvement in the ADHD field has resulted in a deep understanding of the patient community, healthcare professionals and other stakeholders engaged in the area, it added

The company has produced a wide range of resources and educational materials of benefit to the patient and professional communities, which it said will continue to be available through The Flynn Forum.

These will be available as an ongoing service and resource in a therapy area, to which Flynn Pharma said it will shortly add more content.

Flynn Pharma and its engagement specialists will continue to be available to work with and assist healthcare professionals and other stakeholders, and look forward to continuing these close relationships, it continued.

Contact Medice UK on 0204 582 2845 or email [email protected] with any specific enquires relating to these products